Biogen Inc. ($BIIB) Stock Forecast: Down 6.0% Today

What is Biogen Inc.?

Biogen (BIIB) is a biotechnology company specializing in therapies for neurological and neurodegenerative diseases, with a focus on multiple sclerosis (MS) treatments and the development of newer drugs.

Why is Biogen Inc. going down?

BIIB stock is down 6.0% on Aug 1, 2025 14:42

• Biogen exceeded earnings and revenue projections for Q2 2025, but its stock faced a downward trend.
• Concerns arose over the drop in sales of MS medications, despite the promising growth exhibited by newer drugs like Leqembi and Skyclarys.
• Investors are exercising caution regarding the company's overall prospects, given the balance between declining sales of MS drugs and gains from newer products.
• While the initial market response to the strong earnings and raised forecasts was positive, uncertainties about Biogen's future performance in the competitive pharmaceutical industry may be dampening investor sentiment.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Why Is Biogen Stock Gaining Thursday? - Biogen ( NASDAQ:BIIB )

Q2 EPS of $5.47 beats $4.06 estimate; sales rose 7% YoY to $2.65 billion, topping $2.32 billion forecast. Leqembi sales jumped 20% QoQ; Skyclarys revenue hit $130.3 million, up from $100 million last year. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

https://www.benzinga.com/markets/earnings/25/07/46764173/biogen-lifts-outlook-as-rare-disease-and-alzheimers-drug-sales-accelerate

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

https://www.zacks.com/stock/news/2644288/biogens-q2-earnings-sales-beat-2025-outlook-raised-stock-up

Biogen Inc. ( BIIB ) Surpasses Q2 Earnings and Revenue Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2643034/biogen-inc-biib-surpasses-q2-earnings-and-revenue-estimates

Biogen ( BIIB ) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

https://www.zacks.com/stock/news/2638346/biogen-biib-q2-earnings-on-the-horizon-analysts-insights-on-key-performance-measures

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

https://www.zacks.com/stock/news/2629089/biogen-gears-up-to-report-q2-earnings-heres-what-to-expect

Trending Today

MarketAxess Holdings Inc. ($MKTX) Stock Forecast: Down 9.6% Today

New York Times Company (The) ($NYT) Stock Forecast: Up 6.3% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 18.2% Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 28.3% Today

Arista Networks Inc. ($ANET) Stock Forecast: Up 17.4% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 22.3% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 7.0% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 10.6% Today

Kohl's Corporation ($KSS) Stock Forecast: Up 5.1% Today

Global Payments Inc. ($GPN) Stock Forecast: Up 8.3% Today

Biogen Inc. Price History

07.02.2025 - BIIB Stock was up 5.2%

• BIIB stock exhibited a bullish trend despite worries about the pricing of Alzheimer's drugs from Biogen and Eli Lilly.
• Investor optimism towards the potential market demand for Biogen's treatments persists despite pricing concerns.
• The bullish movement reflects confidence in Biogen's capacity to address pricing challenges and advance pioneering therapies in neurology.

01.04.2025 - BIIB Stock was up 3.7%

• BIIB stock surged as investors were impressed by the company's strong performance in the first quarter of 2025.
• Despite Sage Therapeutics' disappointing earnings, BIIB's robust financial results and promising outlook for key metrics exceeded Wall Street estimates, driving up the stock price.
• The market reacted favorably to BIIB's Q1 outlook, indicating confidence in the company's ability to deliver solid results and maintain its position as a key player in the biotech industry.
• Overall, BIIB's bullish movement can be attributed to its strong fundamentals and positive market expectations, contrasting with the underperformance of some of its industry peers.

06.04.2025 - BIIB Stock was down 5.1%

• Following its Q1 earnings release, BIIB witnessed a significant decrease in stock value.
• BIIB outperformed earnings projections, posting an EPS of $3.02 compared to the estimated $2.52, and recorded a revenue surge to $2.43 billion, exceeding the expected $2.23 billion.
• Despite the positive earnings outcome, BIIB's stock faced a decline, potentially due to the mixed Q1 performance and the company's downward revision of its EPS guidance for the year.
• The market response to the revised guidance hints at apprehensions regarding future growth and performance, contributing to the bearish movement in BIIB's stock price today.

31.04.2024 - BIIB Stock was up 5.3%

• BIIB stock rose following marketing authorization from the European Commission for Qalsody, a treatment for a rare genetic form of Amyotrophic Lateral Sclerosis (ALS).
• The approval of Qalsody contributed to increased investor confidence in Biogen's product pipeline and potential revenue growth.
• Despite a legal challenge in the form of a securities class action lawsuit, market sentiment was largely driven by the positive EU approval, leading to a bullish trend in BIIB stock.
• This approval highlights Biogen's dedication to addressing medical needs and expanding its range of therapies with innovative solutions.

26.06.2024 - BIIB Stock was down 8.2%

• The rejection of Biogen and Eisai's Alzheimer's drug, lecanemab, by the European Medicines Agency, citing concerns about its efficacy in early-stage Alzheimer's, led to a notable decrease in Biogen's stock value.
• The negative feedback from the Committee for Medicinal Products for Human Use (CHMP) highlighted the regulatory challenges faced by both companies, impacting investor trust in the drug's potential success.
• This rejection emphasizes the difficulties in creating effective Alzheimer's treatments and the necessity for strong clinical evidence to support approval, resulting in a pessimistic outlook on Biogen's stock.
• As attention shifts to Biogen's upcoming second-quarter earnings call, investors are eager to learn how the company plans to address this setback and navigate the regulatory environment for its Alzheimer's therapy.

26.06.2024 - BIIB Stock was down 7.3%

• The rejection of Biogen's Alzheimer's treatment, Leqembi, by the European drug regulator, citing concerns about its effectiveness and serious side effects, likely influenced the bearish market activity in BIIB stock.
• The unfavorable updates on the regulatory evaluation of Lecanemab for Early Alzheimer's Disease in the European Union may have exacerbated investor uncertainty and pushed down the stock price.
• The ongoing inquiry by Bragar Eagel & Squire, P.C. into potential claims against Biogen Inc. might have raised doubts about the company's future, affecting investor confidence and contributing to the bearish market trend.

26.06.2024 - BIIB Stock was down 8.1%

• The rejection of the Marketing Authorization Approval (MAA) for lecanemab by the Committee for Medicinal Products for Human Use (CHMP) in the European Union has significantly impacted Biogen Inc.'s stock performance.
• The negative opinion on lecanemab's effectiveness in treating early Alzheimer's disease has raised concerns among investors about the future prospects of the drug and its potential market success.
• The regulatory hurdles faced by Biogen Inc. and its partner have highlighted the uncertainties surrounding the approval and commercialization of innovative therapies in the healthcare sector.
• The market's reaction to the news reflects the sensitivity of biopharmaceutical stocks to regulatory decisions and underscores the importance of robust clinical data in gaining approval for novel treatments.

04.03.2025 - BIIB Stock was down 5.0%

• BIIB's stock likely dropped due to the positive announcement of its experimental Alzheimer's drug receiving FDA's fast track designation, potentially heightening optimism for its future success.
• Eli Lilly's Alzheimer's drug received a negative assessment from the European Medicines Agency (EMA), indirectly benefitting Biogen by reducing competition in the Alzheimer's treatment sector.
• Investor sentiment appears to favor Biogen over Eli Lilly, given the challenges the latter faces in gaining regulatory approval for its Alzheimer's drug.
• The divergent paths of the two companies in Alzheimer's drug development may have influenced market outlook towards Biogen, contributing to the downward movement in its stock value today.

13.01.2025 - BIIB Stock was up 5.3%

• Biogen reported better-than-expected earnings for its fourth quarter, with adjusted EPS beating consensus estimates.
• Despite the positive earnings report, Biogen's 2025 EPS guidance fell short of expectations, leading to some analyst downgrades.
• The market reacted positively to Biogen's cost-cutting measures and the potential of new drugs like Leqembi, which are expected to offset revenue declines from existing products.
• Overall, the bullish movement in Biogen's stock can be attributed to the company's strong financial performance in Q4, despite some concerns about future earnings guidance.

12.01.2025 - BIIB Stock was down 5.1%

• Despite surpassing earnings and revenue projections in Q4, BIIB experienced a bearish market movement, suggesting potentially elevated market anticipations.
• The projection of profits fell below expectations despite efforts such as cost reductions and the introduction of new medications like Leqembi, indicating possible investor dissatisfaction with the company's future prospects.
• An increase in optimistic positions on BIIB through options trading potentially heightened market volatility and profit-taking, contributing to the downward trend.
• The decrease in sales of multiple sclerosis treatments and Spinraza was balanced by revenues from new drugs, but this may not have met investor expectations, resulting in the bearish market movement.

12.01.2025 - BIIB Stock was down 8.1%

• Biogen exceeded expectations with cost reduction efforts and the launch of Leqembi, but a lower profit outlook caused a decline in the stock price.
• The FDA's approval of a maintenance dosing regimen for Leqembi in Alzheimer's was a positive development, while decreased sales of multiple sclerosis drugs and Spinraza likely impacted revenue.
• Investor optimism in the options market suggests confidence in the long-term potential of Biogen's new drugs, despite short-term profit concerns.
• The forthcoming Q4 earnings report will be essential in offering more insight into the company's financial performance and the effects of new drugs on revenue.

01.07.2025 - BIIB Stock was down 6.0%

• Biogen exceeded earnings and revenue projections for Q2 2025, but its stock faced a downward trend.
• Concerns arose over the drop in sales of MS medications, despite the promising growth exhibited by newer drugs like Leqembi and Skyclarys.
• Investors are exercising caution regarding the company's overall prospects, given the balance between declining sales of MS drugs and gains from newer products.
• While the initial market response to the strong earnings and raised forecasts was positive, uncertainties about Biogen's future performance in the competitive pharmaceutical industry may be dampening investor sentiment.